Leyla O. Shune, MD

Healthcare professionals emphasize the importance of balancing treatment options with patient priorities, focusing on individual goals and quality of life.

Personalized treatment decisions for pancreatic neuroendocrine tumors consider patient history, toxicity profiles, and lifestyle preferences for optimal outcomes.

Personalized treatment decisions for pancreatic neuroendocrine tumors consider patient history, toxicity profiles, and lifestyle preferences for optimal outcomes.

Explore treatment options for pancreatic neuroendocrine tumors, focusing on patient goals, disease pace, and innovative therapies for optimal outcomes.

Understanding the prognosis of pancreatic neuroendocrine tumors reveals critical factors influencing treatment options and patient outcomes.

Discover the latest insights on axatilimab and belimumab for chronic GVHD, highlighting efficacy, safety, and innovative treatment combinations.

Explore the latest advancements in treating sclerotic skin disease and pulmonary involvement with effective therapies like axetilimab and baramitsode.

Explore the assessment and treatment options for chronic graft versus host disease, focusing on organ involvement and second-line therapies.

A 52-year-old woman experiences chronic GvHD post-stem cell transplant, showcasing complex symptoms and treatment challenges. Discover her journey and management strategies.

A 52-year-old woman experiences chronic GvHD post-stem cell transplant, showcasing skin and joint symptoms, requiring ongoing steroid management.

Explore effective treatment strategies and multidisciplinary approaches for managing chronic graft-versus-host disease post-allogeneic stem cell transplant.

Leyla O. Shune, MD, looks to the future of treatment for patients with chronic graft-versus-host disease (cGVHD).

Leyla O. Shune, MD, discusses sequencing agents in the in current treatment paradigm for chronic graft-versus-host disease, given the multitude of available FDA-approved agents and additional treatments emerging on the horizon.

Leyla O. Shune, MD, discusses results from an interim safety analysis of a randomized phase 2 study exploring axatilimab in combination with ruxolitinib in patients with newly diagnosed chronic graft-versus-host disease.

Leyla O. Shune, MD, discusses an expanded access program in the United States that administered axatilimab to patients with chronic graft-versus-host disease. Specifically, she highlights the tolerability of axatilimab in the real-world setting.

Leyla O. Shune, MD, describes the available treatment options for patients with chronic graft-versus-host disease who are steroid refractory/dependent. She also discusses treatment approaches and results with these agents in clinical trials and in real-world settings.

Addressing Treatment Challenges in Chronic Graft-Versus-Host Disease